ESC Congress - European Society of Cardiology Congress

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

There are several roles pharmacists can play in managing patients with cardiovascular disease, including blood pressure and medication monitoring.

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care.

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the vexing problem of patients who fail to fill or take recommended medications.

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the digital innovations that will have major effects on the cardiovascular field in years to come.

In this clip, Deepak Bhatt, MD, discusses how pharmacists should counsel patients taking aspirin and rivaroxaban, if approved.

In this clip, Deepak Bhatt, MD, discusses the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

In this clip, Steven Nissen, MD, of the Cleveland Clinic discusses some new data on anti-inflammatories and cardiovascular events that were presented this week at the European Society of Cardiology.